Last reviewed · How we verify
SARS-CoV-2 mRNA vaccine
The SARS-CoV-2 mRNA vaccine works by instructing cells to produce a piece of the SARS-CoV-2 virus, triggering an immune response to fight the virus.
The SARS-CoV-2 mRNA vaccine works by instructing cells to produce a piece of the SARS-CoV-2 virus, triggering an immune response to fight the virus. Used for Prevention of COVID-19 disease caused by SARS-CoV-2 virus.
At a glance
| Generic name | SARS-CoV-2 mRNA vaccine |
|---|---|
| Sponsor | TruDiagnostic |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
This is achieved through the use of messenger RNA (mRNA) that encodes for a specific protein from the SARS-CoV-2 virus. Once the mRNA is taken up by cells, it is translated into the protein, which is then recognized by the immune system as foreign, triggering an immune response. This immune response helps to protect against future infections with the SARS-CoV-2 virus.
Approved indications
- Prevention of COVID-19 disease caused by SARS-CoV-2 virus
Common side effects
- Pain, redness, or swelling at the injection site
- Fatigue
- Headache
- Muscle pain
- Chills
- Nausea
- Diarrhea
- Fever
Key clinical trials
- A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations (PHASE4)
- Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction (PHASE4)
- A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults (PHASE1)
- Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals (PHASE2, PHASE3)
- Evaluation of Full Versus Fractional Dose of COVID-19 Vaccine Given as a Booster for the Prevention of COVID-19 in Adults in Mongolia. (PHASE3)
- COVID-19 Breakthrough Infection in Fully Vaccinated People and in People Who Received a Booster Dose
- Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population (PHASE2)
- Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19 (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SARS-CoV-2 mRNA vaccine CI brief — competitive landscape report
- SARS-CoV-2 mRNA vaccine updates RSS · CI watch RSS
- TruDiagnostic portfolio CI